we do need biomarkers. We need to know whether or not there is scope for this specific treatment to identify a subset of patients, which is the holy grail of of oncology, precision,

Aug 7, 2026 / receipt

I'll move on to our 2808 program. This is a program that we're evaluating in patients with multiple myeloma... We haven't enrolled our first patient yet, but we hope to have that happen very soon.

Aug 7, 2026 / receipt

Their primary focus has been on reducing third-party supplier rates, and we have seen strong progress in contract rates for raw materials, components, clinical, travel, and consulting services.

Aug 1, 2024 / receipt, needs a key / Jamie Mock, CFO | earnings call 2024-08-01 | transcript b5472410-2d12-4434-bec7-88543feb9018 | chars 10600-10793 | segment 11

one of the major issues that we struggle with is is the development and the management of immune related adverse events. | This highlights a significant operational challenge in clinical trials, sugge

company_statement / Aug 7, 2026 / receipt

we haven't assessed the difference uh the CD4 and CD3 population in our T-cell assessments. Uh but we will be doing so | This indicates a planned data analysis initiative for their T-cell assessments,

company_statement / Aug 7, 2026 / receipt

remarkably, despite all of the success, we still have more work to do. | This acknowledges a need for continued innovation in melanoma treatment, creating an opening for vendors with novel R&D or clin

company_statement / Aug 7, 2026 / receipt

and ultimately those are the toxicities that we worry the most about. | Leadership is highly focused on managing and mitigating severe treatment-related toxicities, indicating a need for solutions in

company_statement / Aug 7, 2026 / receipt

it's uh an event driven study and we have to wait for the events to mature before we can run our first analysis. | This highlights a dependency on unpredictable clinical trial event rates, creating an

company_statement / Aug 7, 2026 / receipt

we're going to move on to the next mechanism. Uh after Intasmeran, uh we also now have uh some cancer antigen therapies including our most uh recent uh presentation which was 4359. | This named drug d

company_statement / Aug 7, 2026 / receipt

practically on an individual patient level is actually very difficult to prove those changes in the tumor micro environment prior to and after treatment. | This highlights a core difficulty in their R

company_statement / Aug 7, 2026 / receipt

together with Moderna we're working on a lot of additional translational end points | This named partnership and focus on new endpoints signals strategic investment in advanced R&D analytics, suggesti

company_statement / Aug 7, 2026 / receipt

it's difficult for patients who don't have accessible tumors and even patients who might have really great responses, we no longer have tissue to be able to biopsy. | This operational pain point in th

company_statement / Aug 7, 2026 / receipt

we have captured some tissue and that analysis is ongoing. | The company is actively analyzing critical tissue data, indicating a timely opportunity for bioinformatics, data visualization, or advanced

company_statement / Aug 7, 2026 / receipt

if you had looked at a uh pipeline slide like this a couple of years ago, it would have been about half the size. | This rapid doubling of the clinical pipeline indicates significant investment and op

ir_statement / Aug 7, 2026 / receipt

our Intisumeran autogene program...it's uh a program that is extraordinarily unique in the field...There's never been a medicine that is quite so individualized as Intisumeran. | This flagship persona

company_statement / Aug 7, 2026 / receipt